Featured News
Tumor‑Infiltrating Lymphocyte Therapy for the Treatment of Metastatic Melanoma
TIL Working Group co-chair Dr. Krishna Komanduri recently co-authored a review in American Journal of Clinical Dermatology. The publication discusses the development of TIL cell therapies, their role in treating patients with melanoma, and exciting advancements in the field. Click here for the full article
Inside the World of Tumour-Infiltrating Lymphocytes and Cell Therapy
When Jeff Pipes was told his melanoma had returned and spread, it felt like the end of the road. Dive into Jeff’s journey from Tennessee to Kentucky, where he meets the scientists and biotech pioneers working to transform cancer care and give patients hope for the future. Click here to watch the full video
The Promise of TIL:
Dr. Betof-Warner's First Patient Infusion
In February 2024, the Food and Drug Administration (FDA) greenlit the first cellular therapy to treat solid tumors…Thanks to the partnership with Stanford’s Advanced Melanoma Program and Blood and Marrow Transplantation (BMT) & Cellular Therapy Program. Stanford treated the first patient in the world with the approved therapy in April of this year. Click here for the full article
Entering a New Era of TIL Cell Therapy Innovation
Cytotherapy December 28, 2024;
TIL Working Group members Rodabe Amaria, Krishna Komanduri, and Adam Schoenfeld, with colleagues, published this recent review of the current state of TIL cell therapy and innovations in the field. Click here for the full article
